21 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 21 of 21 clinical reviews.
Addyi (flibanserin) carries an FDA boxed warning against alcohol. Learn exactly why the interaction is dangerous, what the clinical data show, how long to avoid drinking, and what your prescriber must document before dispensing.
A guide to bremelanotide (Vyleesi, PT-141) for hypoactive sexual desire disorder in women, including FDA approval details, dosing, side effects, and how it compares to flibanserin, vaginal estradiol, vaginal DHEA, and compounded testosterone cream.
A guide to bupropion for SSRI-induced sexual dysfunction, plus evidence on flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA (prasterone) for women's sexual health.
Evidence-based review of testosterone therapy for low libido in women, including HSDD diagnosis, trial data from APHRODITE and ADORE, FDA-approved alternatives, and clinical dosing guidance.
A guide to compounded oxytocin, flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA for women's sexual health, including doses, evidence, and how to choose.
A guide to compounded testosterone cream for women, covering doses, clinical evidence, comparisons with vaginal estradiol and DHEA, flibanserin, and bremelanotide, and how to get a prescription.
A guide explaining how estrogen, progesterone, and testosterone-based HRT affect female libido, what the clinical evidence shows, and when FDA-approved or off-label treatments are appropriate.
A guide to dyspareunia covering genitourinary syndrome of menopause, vaginismus, HSDD, female orgasmic disorder, and treatments including topical estrogen, ospemifene, pelvic floor PT, and flibanserin.
A guide to female orgasmic disorder (FOD), covering diagnostic criteria, contributing conditions like HSDD and GSM, and evidence-based treatments including flibanserin, ospemifene, pelvic floor PT, and cognitive behavioral therapy.
A guide to HSDD in women: diagnostic criteria, FDA-approved treatments including flibanserin and bremelanotide, off-label hormonal options, and how related conditions like GSM, vaginismus, and dyspareunia affect sexual desire.
A guide to ospemifene (Osphena) for dyspareunia and vaginal atrophy, with dosing, safety data, head-to-head comparisons with vaginal estradiol, prasterone, flibanserin, and bremelanotide, and a decision framework for choosing the right therapy.
A guide to sexual changes after hysterectomy, covering libido shifts, orgasm changes, genitourinary syndrome of menopause, vaginismus, HSDD, and evidence-based treatment options.
A guide to post-SSRI sexual dysfunction in women, covering PSSD mechanisms, HSDD, female orgasmic disorder, GSM overlap, vaginismus, and evidence-based treatments including flibanserin, bupropion, PT-141, and hormone therapy.
A clinical comparison of prasterone (Intrarosa) and vaginal estradiol for genitourinary syndrome of menopause, covering mechanism, efficacy data, safety, cost, and how to choose.
PT-141 (bremelanotide) causes nausea in up to 40% of users and transient skin darkening in roughly 1 in 7 women. Learn the mechanisms, management strategies, and how Addyi's alcohol restriction compares.
Surgical menopause causes hormone levels to drop within 24 hours, often with more severe symptoms and earlier heart and bone risks than natural menopause.
Evidence-based guide to testosterone cream dosing for women, including vaginal estradiol cream dosing and PT-141 (bremelanotide) dosing. Learn recommended doses, application sites, monitoring, and safety considerations backed by clinical trials and guidelines.
A clinical review of trazodone's off-label use for female sexual dysfunction, with an honest look at the limited trial evidence, compared against FDA-approved options: flibanserin, bremelanotide, vaginal estradiol, and vaginal DHEA (prasterone).
Evidence-based dosing guide for vaginal estradiol (cream, ring, insert, tablet) plus PT-141 and testosterone cream dosing for women.
A comprehensive clinical guide to vaginismus, dyspareunia, HSDD, female orgasmic disorder, and genitourinary syndrome of menopause. Covers diagnosis criteria, FDA-approved treatments, and pelvic floor therapy protocols.
Painful sex after menopause is caused by estrogen loss that thins vaginal tissue, reduces lubrication, and triggers GSM. Local estrogen, systemic HRT, ospemifene, testosterone, and lifestyle changes can restore comfort and desire. Learn which treatment fits your situation.